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INTERLEUKIN-6, a potent pro-inflammatory cytokine, might
be involved in Behet’s disease (BD) pathological path-
ways. We investigated IL-6 levels in sera and synovial
fluids collected from BD patients. The IL-6 production
was also studied in vivo, by measuring its activity in
culture supernatants of PBMC and alveolar macrophages,
stimulated or not with LPS. The patients with BD were
compared to RA patients and healthy controls. High IL-6
levels were observed in sera, synovial fluid and LPS-
stimulated PBMC supernatants, from active BD patients,
similar to those of RA patients. Alveolar macrophages
production of IL-6 was significantly elevated in two active
BD patients with an interstitial pneumonia, when com-
pared to controls. These elevated levels of IL-6 suggest its
involvement in the inflammatory sites of BD, which may
be related to the progression of the acute lesions, at least
in the joints and in the lungs.
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Introduction
Behet’s disease (BD) is a multisystemic disease,
mainly observed in Mediterranean areas and in
Japan; it is characterized by oral and genital
ulcerations, associated with ocular and skin lesions,
arthralgia, neurological involvement, and pulmon-
ary manifestations.
Elevated levels of interleukin-1 (IL-1), tumour
necrosis factor- (TNF-), soluble interleukin-2
receptor
2 and gamma-interferon
3-s have been
observed in patients with active Behet’s disease
(BD), suggesting the involvement of these
cytokines in the inflammatory process.
Among the immunological factors that have been
recently involved in the inflammatory manifes-
tations, interleukin-6 (IL-6) plays a prominent
role.
6 IL-6 has pleitropic biological effects, includ-
ing human T-cell activation,
7 and B-cell prolifera-
tion and differentiation.
The aim of our study was to evaluate in BD
patients IL-6 level in sera and IL-6 production by
blood mononuclear cells (PBMC) into culture
supernatants. Moreover, IL-6 was quantified in two
local inflammatory sites: synovial fluid and culture
supernatants of alveolar macrophages obtained by
bronchoalveolar lavage.
Materials and Methods
Patients’Thirty patients with BD, who fulfilled the
criteria proposed by the International Study
Group for Behet’s Disease
9 were studied, 28
men and two women, with a mean (+ SEM) age
of 34__+ 3 years. Twenty patients had active
disease, and ten inactive disease. The clinical
characteristics and the treatment of active BD
patients are shown in Table 1. Two patients with
active BD had also pulmonary manifestations" a
chronic cough associated to interstitial shadows
on the chest roentgenogram.
1 These patients
received no treatment.
Six patients with inactive BD received thalido-
mide therapy for 6 to 38 months with an
average of 20 months,
l the other four patients
with inactive disease received corticosteroids.
Ten patients with rheumatoid arthritis (RA),
meeting the Arthritis Rheumatism Association
criteria, were studied during acute flares of
synovitis. All RA patients were on standard
therapy including nonsteroidal anti-inflammatory
drugs. Most patients were female, with a mean
(+ SEM) age of 47 + 12 years.
Twenty healthy age-and-sex-matched subjects
were studied as controls.
Serum and synovialfluid: Serum samples were collected
from all patients and control subjects. Synovial fluid
was obtained from the ten RA patients and ten
active BD patients with arthritis. Freshly aspirated
synovial fluids were collected into heparinized
tubes (10 U ml-), treated with 1.5 U ml-
hyal-
uronidase for 30min at 37C, centrifuged at
1 200 x g to remove cellular debris and stored at
-20C until use.
Peripheral blood mononuclear cells (PBMC) IL-6 produc-
tion by PBMC was studied in active BD (ten cases),
inactive BD (ten cases), RA patients (ten cases) and
ten healthy controls. PBMC were separated by
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Table 1. Clinical characteristics of active BD patients
Number Age (years) Sex Oral ulcers Genital ulcers Arthritis Uveitis Treatment
32 M + + + + CS
2 45 M + + + + NT
3 34 M + + + NT
4 27 M + + + NT
5 38 F + + + NT
6 40 M + + + NT
7 37 M + + + NT
8 26 M + + + CS
9 33 F + + + + NT
10 35 M + + + + NT
11 36 M + + + + CS
12 48 M + + + NT
13 43 M + + + + NT
14 24 M + + + NT
15 29 M + + + + NT
16 45 M + + + CS
17 37 M + + + + NT
18 36 M + + + + NT
19 45 M + + + NT
20 22 M + + + + NT
+ or with or without symptoms; NT without treatment, CS daily 0.5 mg kg -1 prednisone
standard Ficoll-Hypaque density gradient cen-
trifugation. PBMC (5 106m1-1) were resus-
pended in RPMI 1640 medium (Gibco, Grand
Island, NY) supplemented with 20 #g gentamycin,
5% AB-positive serum and 2 mmol 1-1 -glutamine.
The final cellular suspension of PBMC contained
20% monocytes. Cells were cultured at a concentra-
tion of 106ml-, for 24h in humidified air
containing 5% CO2 at 37C, in the presence or
absence of 20/2g ml-
of Escherichia coli lipopoly-
saccharide (LPS; Sigma, St Louis, MO). Super-
natants were collected after 24 h of culture.
Bronchoalveolar lavage: Bronchoalveolar lavage (BAL)
was performed in two patients with active BD
having a chronic cough associated to interstitial
shadows on the chest roentgenogram, and five
control subjects, using a fibre-optic bronchoscope.
The right middle lobe was lavaged with 50 ml
aliquots of sterile 0.9% sodium chloride to a total
of 200 ml. The lavage fluid was gently aspirated
after each aliquot and collected into a sterile,
siliconized glass bottle and maintained at 4C. The
lavage fluid was filtered through a coarse gauze and
centrifuged at 480 g at 4C. The cell pellet was
then washed twice with RPMI 1640 medium.
Alveolar macrophages (AM) were enriched by
adherence to plastic (Costar, Cambridge, MA) for
24 h at 37C and 5% CO2. The adherent cells were
collected and the percentage ofAM ranged between
90 and 96%. The AM were placed into the culture
medium at a density of 106 AM/ml, and assayed for
IL-6 production with or without LPS stimulation.
After 24 h, AM culture supernatants were collected.
Assessment of IL-6 activity: IL-6 activity was tested
using an IL-6-dependent mouse hybridoma 7TD1,
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cultivated in flat-bottomed microtitre plates con-
taining 2000 cells/well in the presence of serial
dilutions of supernatants or sera. After 4 days of
culture, the number of surviving cells was
determined by a colorimetric assay as reported by
Van Damme et al.
12 Hybridoma growth factor/IL-6
activity was expressed in U m1-1, defined as the
dilution giving half the maximal proliferation of
7TD1 cells. One unit corresponds to approximately
5 pg ml- of IL-6. 7TD1 cells respond neither to
ILl, TNF0, IL2, IFN0 and 2, nor to any of the
known colony-stimulating factors other than IL-6.
Biological activity of IL-6 samples was completely
neutralized by adding monospecific rabbit poly-
clonal anti-recombinant human IL-6 antibodies to
test samples. To eliminate inhibitory effects present
in undiluted sera and to determine the lower limit
of detection of the assay, IL-6 activity in sera was
measured as such and by adding 100U of
recombinant cytokine. The standard used in these
assays was r-IL-6 (Genzyme, Boston, MA).
IL-6 activity in experimental samples was tested at
least three times.
Statistical analysis" Data were analysed with a Stat
Work program on a Macintosh Classic computer.
All results are expressed as (mean+SEM).
Comparisons of mean values were performed with
the unpaired Student’s t-test. Non parametric
comparisons were .conducted with the Mann-
Whitney U-Test, using Cricket Stat Work.
Results
IL-6 in serum" Low levels of IL-6 activity could be
detected in the serum from all healthy individualsIL-6 in Behet’s disease
tested (4.5 _-t-1.9 U ml-1). In patients with active
BD, the values were significantly increased
(19.8 -t- 9 U ml-1) (Fig. 1) compared to control
subjects (p<0.001)" 16 patients with active
BD stage and without treatment had increased
levels of IL-6 (>--12 U ml-1). The four other
active BD patients receiving steroid therapy had
low levels of IL-6 (<6 U ml-1). Patients with
inactive disease had similar IL-6 levels as controls
(5.3-t-2.3 U ml-1). Patients with RA had also
increased seric IL-6 levels (16.7+/-3.2Um1-1;
p < 0.01) when compared to healthy controls. No
statistical difference of seric IL-6 levels between
active BD and RA patients was observed.
IL-6 in PMBC culture supernatants: IL-6 was undetect-
able in monocytes depleted T-cell cultures either
from BD patients, RA patients or healthy controls.
Spontaneous IL-6 production was detected in
active BD patients (898-t-78.2 U ml-1), in in-
active BD patients (272-t-71.4 U ml-1), in RA
patients (717 -t- 176.5 U m1-1) and in healthy
controls (196 -1- 31.7 U ml-1). Spontaneous IL-6
production was significantly increased in active BD
patients and in RA patients (Fig. 2) when compared
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FIG. 1. Serum levels of interleukin-6 (IL-6) in healthy
controls (4.5 +_ 1.9 U ml-1), in patients with active Beh:et’s
disease (19.8 ___
9 U m1-1), in patients with inactive Behet’s
disease (5.3 -t- 2.3 U m1-1) and in patients with Rheumatoid Arthritis
(16.7 _+ 3.2 U m1-1).
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FIG. 2. Spontaneous and LPS-induced production of IL-6 (U m1-1) by
PBMC from patients with active and inactive Behet’s disease, patients
with rheumatoid arthritis and from healthy controls.
to inactive BD and control subjects (p < 0.01).
There was no dierence in spontaneous IL-6
production between patients with inactive BD and
healthy controls.
After LPS stimulation IL-6 production was
significantly increased (p < 0.01) in patients with
active BD (2980 518 U ml-1), in inactive BD
patients (2390 __+ 310 U ml-1), and in RA patients
(2950-t-873 U m1-1) (Fig. 2) as compared with
healthy controls (1100 -t- 117 U ml-1).
IL-6 in synovialjquid: IL-6 was detected in all synovial
fluid samples tested. IL-6 levels were similar in joint
fluids obtained from patients with active BD
(1835 +__ 703 U ml-1) and from RA patients
(2010 -t- 504 U ml-1).
IL-6 secretion from alveolar macrophages from two patients
with active BD" The total BAL cell yield in BD
patients (9.9 x 106 and 11 x 106 ceils m1-1) was
in the same range as that of the normal group
(9.7 x 106 cells ml-1). BD patients had a greater
percentage of lymphocytes in lavage (17% and 12%)
than control population (6.8 q- 1.4%). The percent-
ages of alveolar macrophages in the BD patients
(83.4% and 79.8%) were decreased when compared
to the healthy controls (93.2 ___
1.6%; p < 0.01).
Alveolar macrophages (AM) isolated from two
patients with active BD and five controls, were
assayed for spontaneous and after LPS-stimulation
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IL-6 production. The level of spontaneous IL-6
production was significantly increased (p < 0.01) in
culture supernatants from the two patients with
BD, 2893 U m1-1 and 2350 U m1-1, as compared
to supernatants of AM from five control subjects
(1200 -+- 122.5 U ml-). After LPS-stimulation, AM
from patients with BD produced 4540 U m1-1 and
4980 U m1-1, twice more than healthy controls
(2240 _--k 194.9 U ml-1).
Thus, spontaneous and after LPS-stimulation
IL-6 production by AM from active BD patients
with interstitial pneumonia was significantly in-
creased compared to controls (p < 0.01).
Discussion
In this study, a high seric IL-6 level from active
BD patients similar to that from RA patients was
shown, while seric IL-6 from inactive BD patients
was in the same range as healthy controls. Moreover
spontaneous and after LPS stimulation IL-6
production by PMBC from active BD patients, was
as high as that from RA patients. Spontaneous IL-6
production from inactive BD patients was similar
to that of control subjects. However after LPS
stimulation, IL-6 production was as high as in
active BD and RA patients.
Thus, seric IL-6 levels seemed to be correlated
to the clinical activity in BD, suggesting that in vivo,
IL-6 is produced only during the clinical
exacerbations. Corticosteroid treatment may
influence directly IL-6 production. It seems to
downregulate in vivo IL-6 production in active BD,
since the patients receiving steroid therapy had
lower seric values. This effect was not observed
with in vitro production of II2-6 by PMBC, since
IL-6 production was high in all active BD patients,
receiving or not corticosteroid therapy.
A moderate level of seric IL-6 may also be due
13 to the presence of a circulating IL-6 receptor,
which diminishes IL-6 detectable activity, acting as
an immunoregulator.
In the synovial fluids, IL-6 was detected at similar
levels in active BD and RA patients. High IL-6
levels have been reported in several autoimmune
diseases such as RA14 and systemic lupus
erythematosus.
15 IL-6 in synovial fluid from active
BD was at a lower level than in RA synovial fluid.
It has been reported that IL-6 production was found
in inflammatory synovium from RA14’16 and BD
patients,
iv
IL-6 is an inflammatory cytokine with multiple
effects including the ability to stimulate or to
enhance the differentiation and the proliferation of
cytotoxic T-cells, and the differentiation of B-cells
into plasma cells
18 as it was shown in systemic lupus
erythematosus (SLE), where the overproduction of
IL-6 contributes to the B-cell hyperactivity.
15 We
have recently reported high cytotoxic T-cell activity
against Herpes Simplex virus
19 and increased
immunoglobulin production in active BD.
2 How-
ever, our data were obtained in vitro, and we have
no evidence about the direct role of IL-6 on B-cell
function.
Alveolar macrophages obtained from two BD
patients with pulmonary manifestations, produced
higher levels of I12-6 spontaneously and after
LPS-stimulation than controls. Furthermore, AM
from BD patients, in contrast to controls, expressed
ICAM-1 antigen (data not shown), that could be
related with the presence of IL-6. This cytokine may
serve as an intermediate trigger regulating the
expression of accessory surface molecules such as
antigens of the MHC system and leukocyte
adhesion molecules on the monocytes/macro-
phages.
21
The increased IL-6 levels in serum and
LPS-stimulated PBMC supernatants, did not argue
against the normal levels of TNF-0 found in vivo.
Increased concentrations of IL-1 and TNF-0 may
be found in vivo only in extreme circumstances,
22
whereas IL-6 is normally detected in the circulation,
and rises rapidly after even minor trauma and
inflammation.
23 IFN-2 and IL-6 are known to
interact either synergistically or antagonistically. In
active BD, the release of gamma-interferon (IFN-),)
is increased. 4’5 It may be responsible for the
enhancement of IL-6 production.
24 On the other
hand, IL-6 may accelerate the inflammatory reaction
by stimulating T- and B-cells, leading to further
IFN-) production.
24
Our aim in investigating in vitro and in vivo IL-6
production, was to study the cell-cell interactions
that are influenced in a positive or a negative
manner by the in vivo release of various mediators.
An exact knowledge of the role played by each
cytokine in BD, may allow to inhibit damaging
cytokine pathways or amplify regulatory pathways
and thereby, have a therapeutic value. Various
micro-organisms have been implicated as aetiologi-
cal agents of BD such as Herpes Simplex virusas
and streptococcal antigens.
2 We are currently
investigating the IL-6 and other cytokines produc-
tion after stimulation with different micro-
organisms.
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